Thymulin

What it is

Thymulin is a thymic peptide originally described in the serum thymic factor literature of the 1970s^{[5 –6 ]}. Bach, Dardenne, Pleau, and colleagues biochemically characterized serum thymic factor as a thymus-dependent nonapeptide^{[5 ]}. Earlier work supported thymic epithelial origin for serum thymic factor activity^{[6 ]}.

The biologically active form is zinc-associated thymulin, often referred to as FTS-Zn^{[7 –8 ]}. Dardenne and colleagues reported that zinc and other metals contributed to serum thymic factor biological activity, and classic work distinguished inactive zinc-free forms from zinc-containing active forms^{[7 –8 ]}. This is why the phrase “zinc-thymulin” appears in both research and commercial discussion.

Thymulin is often confused with other thymus-related products. It is not thymosin alpha-1, which is a different 28-amino-acid peptide with separate international drug history. It is not thymosin beta-4 or TB-500. It is also not the same as thymalin or crude thymus extracts. This distinction matters because safety and efficacy data are not interchangeable across thymic products.

Most modern thymulin research is preclinical. Studies have investigated thymulin in inflammatory pain, asthma models, autoimmune disease models, type 1 diabetes models, and central nervous system inflammation^{[10 –15 ]}. Administration routes and delivery systems vary widely, including gene-therapy-style nanoparticle approaches in animal asthma research^{[10 –11 ]}. This page does not provide dosing or clinical-use instructions.

Regulatory status

Thymulin is not FDA-approved in the United States for immune support, infection prevention, autoimmune disease, asthma, allergies, hair loss, anti-aging, thymic rejuvenation, or any other indication. No FDA-approved thymulin prescribing label was identified for this draft.

503A Category 3

FDA’s 503A framework states that bulk drug substances used by state-licensed physicians and pharmacists must meet a USP/NF monograph pathway, be components of FDA-approved drug products when no monograph exists, or appear on FDA’s 503A bulks list^{[1 ]}. FDA’s April 22, 2026 503A category list places Thymulin acetate in Category 3, which FDA defines as nominated without adequate support^{[2 ]}.

FDA states that Category 3 substances are not eligible for the interim policy that applies to Category 1 substances and that FDA would consider taking action against compounders under general enforcement policies for compounding with such substances^{[1 ]}. This draft therefore treats thymulin acetate as not currently available through FDA-compliant routine 503A compounding channels^{[1 –2 ]}.

503B and controlled-substance status

For 503B outsourcing facilities, FDA states that bulk drug substances generally must be on the 503B bulks list or be used for a drug on the FDA shortage list at the time of compounding, distribution, and dispensing^{[3 ]}. No 503B pathway for thymulin was identified during this review^{[3 ]}.

Thymulin is not listed in federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[4 ]}. Date of last regulatory verification: May 7, 2026.

Research summary

The foundational evidence is biochemical and immunologic. Bach and colleagues reported the biochemical characterization of a serum thymic factor in Nature in 1977^{[5 ]}. Dardenne and colleagues reported epithelial origin for serum thymic factor activity in thymus-product studies^{[6 ]}. Pleau and Dardenne’s later work examined zinc-dependent antigenicity and activity, and Dardenne and colleagues reported that zinc contributed to the biological activity of serum thymic factor^{[7 –8 ]}.

The classic thymulin literature supports a biologically active thymic peptide concept, not a modern FDA-approved immune therapy. Reggiani and colleagues reviewed thymulin physiology and therapeutic potential, noting broad endocrine-immune interactions and experimental interest^{[9 ]}. Review-level potential should not be confused with clinical evidence for commercial thymulin products.

Asthma — nanoparticle gene therapy in animals

Asthma research includes nanoparticle-mediated gene therapy approaches rather than simple peptide administration. da Silva and colleagues reported that DNA nanoparticle-mediated thymulin gene therapy prevented airway remodeling in an experimental allergic asthma model^{[10 ]}. A later Science Advances study reported that nanoparticle-based thymulin gene therapy therapeutically reversed key pathology of experimental allergic asthma^{[11 ]}. These animal gene-delivery studies do not establish that injected or topical thymulin treats asthma in humans.

Pain and autoimmune models

Inflammation and pain research is also preclinical. Nasseri and colleagues reported that thymulin treatment attenuated inflammatory pain by modulating spinal cellular and molecular signaling pathways^{[12 ]}. Lunin and colleagues studied thymulin and an NF-kappaB signaling inhibitor in a severe autoimmune disease mouse model^{[13 ]}. These studies suggest immunomodulatory biology but not human efficacy.

Type 1 diabetes and CNS inflammation models

Other animal models include type 1 diabetes and central nervous system inflammation. Novoselova and colleagues reported protective effects of thymulin and peroxiredoxin 6 in streptozotocin-induced type 1 diabetes in mice^{[14 ]}. Lunin and colleagues reported protective effects of exogenous peroxiredoxin 6 and thymulin on blood-brain-barrier conditions in an experimental multiple sclerosis model^{[15 ]}.

Limited human data

Human clinical evidence for thymulin as a therapeutic drug is thin. Some research has examined serum thymulin activity as a biomarker of zinc status, including comparison with other measures of marginal zinc deficiency^{[16 ]}. Biomarker research does not prove that administered thymulin treats immune deficiency, infection risk, asthma, autoimmune disease, aging, or hair loss.

Calibration

The key evidence-quality issue is that much of thymulin’s modern experimental literature uses animal models or specialized delivery methods rather than ordinary peptide replacement^{[10 –15 ]}. In asthma models, for example, the intervention was nanoparticle-mediated thymulin gene therapy, not a commercial thymulin injection or topical product^{[10 –11 ]}. Those delivery systems have different pharmacology, safety questions, and regulatory implications.

The zinc literature should also be interpreted narrowly. Classic findings that zinc is required for thymulin activity support the biology of FTS-Zn^{[7 –8 ]}, and later biomarker work compared thymulin activity with other markers of marginal zinc deficiency^{[16 ]}. Those data do not show that zinc-thymulin products reverse thymic involution, prevent infections, treat autoimmune disease, or improve vaccine responses.

Claims about immune restoration, “thymus rejuvenation,” or general anti-aging are therefore not substantiated by the cited literature. The scientifically defensible summary is that thymulin is a biologically interesting thymic peptide with zinc-dependent activity and mostly preclinical therapeutic research.

No modern, adequately powered randomized clinical trial of a defined thymulin drug product was identified for immune deficiency, asthma, autoimmune disease, infections, hair loss, or aging. Until such data exist, thymulin should remain categorized as research-only.

In practical terms, thymulin should be categorized as a legacy thymic-hormone research peptide with renewed online interest, not as a modern approved immunotherapy.

Public discourse

No qualifying public-discourse entries were identified for this page. Search results included Reddit threads, clinic pages, thymic-peptide marketing pages, and confusion between thymulin, thymalin, and thymosin alpha-1. No accessible named-source podcast, article, or transcript with a verifiable quote meeting this site’s citation standard was identified.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

No FDA-approved thymulin product label exists, so there is no FDA-reviewed adverse-reaction table, contraindication list, interaction profile, pregnancy/lactation section, or long-term surveillance dataset. This is a central safety limitation.

Theoretical concerns

Theoretical concerns follow from immune and endocrine-immune activity. A compound that modifies thymic or inflammatory signaling could have unpredictable effects in autoimmune disease, active infection, malignancy, transplant medicine, immunosuppression, or inflammatory disorders. These concerns are not resolved by animal-model benefit.

Zinc dependence and product complexity

Zinc dependence adds another layer of complexity. Classic studies showed that zinc contributes to serum thymic factor biological activity^{[7 –8 ]}, but that does not mean zinc-thymulin products are interchangeable or clinically validated. Formulation, metal binding, salt form, stability, sterility, and identity would all matter for any drug product.

Nomenclature confusion as a safety issue

Grey-market thymulin products create risks of mislabeling and product confusion, particularly with thymosin alpha-1, thymosin beta-4/TB-500, thymalin, and thymus extracts. These products have different sequences and evidence bases.

For editorial purposes, nomenclature is a safety issue. A patient searching for thymulin may encounter products labeled thymalin, thymosin, thymus peptide, or zinc-thymulin. Unless the exact sequence, salt form, manufacturing standard, and regulatory status are verified, those products should not be treated as equivalent.

Available through

Thymulin is not currently available through FDA-compliant prescription or compounding channels in the United States as of 2026-05-07^{[1 –3 ]}. ProPeptideGuide does not link to or endorse grey-market vendors.